???global.info.a_carregar???
Rita Azevedo graduated in Biochemistry from the Instituto Universitário de Ciências of CESPU group in 2012. She started her research pathway in the field of pharmacogenetics by integrating the Molecular Oncology Group & Viral Pathology – Research Centre, Portuguese Institute of Oncology – Porto, for two years. Rita Azevedo completed an MSc in Medical Informatics in 2014 from the Faculty of Medicine of the University of Porto, with a dissertation about mobile health (mHealth) for disease self-management. In 2014 she started her PhD degree in Pathology and Molecular Genetics at the Abel Salazar Biomedical Sciences Institute of the University of Porto aimed to develop novel therapeutic strategies based on glycoproteins in bladder cancer, with funding from a grant from the Foundation for the Science and Technology (FCT) (SFRH/BD/105355/2014). She also joined the Experimental Pathology and Therapeutics Group of the Portuguese Institute of Oncology – Porto, the host institution where the PhD work has been developed. Her thesis has set a roadmap for glycobiomarker discovery in bladder cancer (cell lines, biopsies, and urine samples), exploring the full potential of glycomics, glycoproteomics, and high-resolution mass spectrometry. Moreover, it has set the foundations for glycoepitopes synthesis and purification, providing the necessary structural and clinical rationale for supporting the development of novel glycan-based theranostics applications. In 2020, Rita Azevedo had her first abroad experience and started as a post-doctoral researcher in the Pulliainen-laboratory at the University of Turku, Finland. She was interested in conducting proteomics in Salmonellosis models and exploring ADP-ribosylation using high-resolution mass spectrometry (DDA). In 2021, she moved to France and started as a research engineer in the François Becher group at CEA Saclay, Ille-de-France. She characterized and quantified tau protein in Alzheimer’s disease using high-resolution mass spectrometry (DDA and PRM), aiming to find novel tau proteoforms as biomarkers. At two months before the end of 2022, she joined as a research engineer to Matondo’s Proteomics Platform UTechS Mass Spectrometry for Biology Utechs (MSBio), Institut Pasteur. Rita Azevedo published 30 scientific articles (11 publications as 1st author, 8 reviews; mean journal impact factor of 4.37) with a cumulative journal impact factor of 125, an H-index of 21 (Scopus), and a total citations number of 1,008 (Scopus, Author ID: 55825758200).
Read full resume ↓
Identification

Personal identification

Full name
Ana Rita Pereira Azevedo

Citation names

  • Azevedo, Rita
  • Pereira Azevedo, Ana Rita

Author identifiers

Ciência ID
251F-01FE-9403
ORCID iD
0000-0002-3015-9675

Websites

Knowledge fields

  • Engineering and Technology - Other Engineering and Technologies
  • Medical and Health Sciences - Health Sciences

Languages

Language Speaking Reading Writing Listening Peer-review
English Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
French Beginner (A1) Beginner (A1) Beginner (A1) Beginner (A1) Beginner (A1)
Education
Degree Classification
2015 - 2019
Concluded
 Patologia e Genética Molecular (Doutoramento)
Major in Sem especialidade
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Development of monoclonal antibodies for bladder cancer based on glycobiomarkers: identification of relevant glycoantigens and synthesis methodologies thereof" (THESIS/DISSERTATION)
 Aprovado
2014 - 2016
Concluded
 Patologia e Genética Básica (Curso de doutoramento (conclusão de unidades curriculares))
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
 17
2012 - 2014
Concluded
 Informática Médica (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
"Development of a Smartphone application for Rheumatoid Arthritis self-management" (THESIS/DISSERTATION)
 17 valores (em 20 valores)
2009 - 2012
Concluded
 Bioquímica (Licenciatura)
Instituto Universitário de Ciências da Saúde, Portugal
"Polimorfismos genéticos do Timidilato Sintetase no tratamento da Artrite Reumatoide" (THESIS/DISSERTATION)
 15 valores (em 20 valores)
Affiliation

Science

Category
Host institution 		Employer
2022/11/02 - 2023/11/30 Contracted Researcher (Research) Institut Pasteur, France
Institut Pasteur, France
2021/03/01 - 2022/09/06 Contracted Researcher (Research) Commissariat a l'energie atomique et aux energies alternatives Centre de Saclay, France
2020/02/01 - 2021/01/31 Postdoc (Research) Turun yliopisto, Finland
2015/03 - 2019/06/04 Researcher (Research) Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2013/10 - 2014/12 Research Trainee (Research) Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2012/02 - 2012/08 Research Trainee (Research) Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Projects

Grant

Designation Funders
2015/03 - 2019/03 Development of monoclonal antibodies for chemoresistant bladder cancer based on glycobiomakers
SFRH/BD/105355/2014
 Fundação para a Ciência e a Tecnologia, I.P.
Outputs

Publications

Conference abstract
  1. Lima, Aurea; Bernardes, Miguel; Azevedo, Rita; Medeiros, Rui; Seabra, Vítor. "Rumo à Medicina Personalizada na Artrite Reumatoide: Polimorfismos no Gene ATIC como Preditores Farmacogenéticos da Resposta Clínica ao Metotrexato". Paper presented in IV Simpósio SPR - Imagiologia, Póvoa do Varzim, 2015.
    Published
  2. Lima, Aurea; Bernardes, Miguel; Azevedo, Rita; Medeiros, Rui; Seabra, Vítor. "Poderão os Polimorfismos no Gene MTHFR Predizer o Perfil de Resposta Clínica ao Metotrexato em Doentes com Artrite Reumatoide?". Paper presented in IV Simpósio SPR - Imagiologia, Póvoa do Varzim, 2015.
    Published
  3. Lima, Aurea; Bernardes, Miguel; Azevedo, Rita; Medeiros, Rui; Seabra, Vítor. "Polimorfismos no ADORA2A como Preditores da Toxicidade ao Metotrexato na Artrite Reumatoide: Um Passo em Direção à Medicina Personalizada". Paper presented in IV Simpósio SPR - Imagiologia, IV Simpósio SPR - Imagiologia, 2015.
    Published
  4. Lima, Aurea; Bernardes, Miguel; Sousa, Hugo; Azevedo, Rita; Medeiros, Rui; Seabra, Vítor. "Prediction of Methotrexate Therapeutic Outcome: Can an Index Risk be more important than a Haplotype approach?". Paper presented in Second ESPT Conference "Pharmacogenomics: From Cell to Clinic", Lisboa, 2014.
    Published
  5. Lima, Aurea; Seabra, Vítor; Bernardes, Miguel; Azevedo, Rita; Sousa, Hugo; Medeiros, Rui. "Role of key TYMS polymorphisms on Methotrexate therapeutic outcome in Rheumatoid Arthritis Portuguese patients". Paper presented in Second ESPT Conference "Pharmacogenomics: From Cell to Clinic", Lisboa, 2014.
    Published
  6. Lima, Aurea; Seabra, Vítor; Bernardes, Miguel; Azevedo, Rita; Sousa, Hugo; Medeiros, Rui. "TYMS polymorphisms and methotrexate therapeutic outcome in rheumatoid arthritis Portuguese patients: analysis of key polymorphisms". Paper presented in European League Against Rheumatism Congress 2014, Paris, 2014.
    Published
  7. Lima, Aurea; Azevedo, Rita; Sousa, Hugo; Bernardes, Miguel; Medeiros, Rui; Seabra, Vítor. "SLC19A1, SLCO1B1 and ABCG2 polymorphisms are associated with Methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients". Paper presented in European League Against Rheumatism Congress 2014, Paris, 2014.
    Published
  8. Lima, Aurea; Bernardes, Miguel; Azevedo, Rita; Sousa, Hugo; Seabra, Vítor; Medeiros, Rui. "SLC22A11 T allele (rs11231809) as a predictor of Methotrexate non-response in Portuguese rheumatoid arthritis patients". Paper presented in XVII Congresso Português de Reumatologia, Algarve, 2014.
    Published
Conference poster
  1. Freitas, Rui; Relvas-Santos, Marta; Pereira Azevedo, Ana Rita ; Soares, Janine; Fernandes, Elisabete; Beatriz Teixeira; Santos, Lúcio; Silva, André M. N.; Ferreira, José Alexandre. Corresponding author: Ferreira, José Alexandre. "Enzymatic synthesis of cancer-associated O-glycopeptides libraries and multivalent protein glycoconjugates: translating synthetic glycoepitopes into cancer glycovaccines". Paper presented in First Summer School in Biomedical Glycoscience, 2022.
  2. Peixoto, Andreia; Fernandes, Elisabete; Gaiteiro, Cristiana; Lima, Luís; Azevedo, Rita; Soares, Janine; Cotton, Sofia; et al. "Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation". Paper presented in 29th International Carbohydrate Symposium (ICS 2018) by Peixoto A, 2018.
Journal article
  1. Ferreira E; Ferreira D; Relvas-Santos M; Freitas R; Soares J; Azevedo R; Afonso LP; et al. "Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.". International journal of molecular sciences (2024): http://europepmc.org/abstract/med/38542435.
    10.3390/ijms25063462
  2. Jacquemin C; Villain N; Azevedo R; Boluda S; Thévenot EA; Fenaille F; Lamari F; Becher F. "Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry.". European journal of mass spectrometry (Chichester, England) (2024): http://europepmc.org/abstract/med/38258392.
    10.1177/14690667231218912
  3. "Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications". Cells 11 8 (2022): 1279-1279. http://dx.doi.org/10.3390/cells11081279.
    10.3390/cells11081279
  4. Gaiteiro, Cristiana; Soares, Janine; Relvas-Santos, Marta; Peixoto, Andreia; Ferreira, Dylan; Paulo, Paula; Brandão, Andreia; et al. "Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion". Theranostics 12 7 (2022): 3150-3177. http://dx.doi.org/10.7150/thno.67409.
    10.7150/thno.67409
  5. Peixoto A; Ferreira D; Azevedo R; Freitas R; Fernandes E; Relvas-Santos M; Gaiteiro C; et al. "Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.". Journal of experimental & clinical cancer research : CR (2021): http://europepmc.org/abstract/med/34108014.
    10.1186/s13046-021-01988-6
  6. Sofia Cotton; Dylan Ferreira; Janine Soares; Andreia Peixoto; Marta Relvas-Santos; Rita Azevedo; Paulina Piairo; et al. "Target Score—A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness". International Journal of Molecular Sciences 22 4 (2021): 1664-1664. https://doi.org/10.3390/ijms22041664.
    10.3390/ijms22041664
  7. Freitas, R.; Relvas-Santos, M.; Azevedo, R.; Soares, J.; Fernandes, E.; Teixeira, B.; Santos, L.L.; et al. "Single-pot enzymatic synthesis of cancer-associated MUC16: O -glycopeptide libraries and multivalent protein glycoconjugates: A step towards cancer glycovaccines". New Journal of Chemistry 45 20 (2021): 9197-9211. http://www.scopus.com/inward/record.url?eid=2-s2.0-85106745147&partnerID=MN8TOARS.
    10.1039/d0nj06021f
  8. Elisabete Fernandes; Rui Freitas; Dylan Ferreira; Janine Soares; Rita Azevedo; Cristiana Gaiteiro; Andreia Peixoto; et al. "Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells". Cancers (2020): https://doi.org/10.3390/cancers12040861.
    10.3390/cancers12040861
  9. Peixoto A; Relvas-Santos M; Azevedo R; Santos LL; Ferreira JA. "Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks.". Frontiers in oncology (2019): http://europepmc.org/abstract/med/31157165.
    10.3389/fonc.2019.00380
  10. Manuel Neves; Rita Azevedo; Luís Lima; Marta I. Oliveira; Andreia Peixoto; Dylan Ferreira; Janine Soares; et al. "Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications". New Biotechnology 49 (2019): 77-87. https://doi.org/10.1016/j.nbt.2018.09.004.
    10.1016/j.nbt.2018.09.004
  11. Azevedo R; Soares J; Gaiteiro C; Peixoto A; Lima L; Ferreira D; Relvas-Santos M; et al. "Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.". Talanta (2018): http://europepmc.org/abstract/med/29674052.
    10.1016/j.talanta.2018.03.028
  12. Azevedo R; Gaiteiro C; Peixoto A; Relvas-Santos M; Lima L; Santos LL; Ferreira JA. "CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.". Clinical proteomics (2018): http://europepmc.org/abstract/med/29983670.
    10.1186/s12014-018-9198-9
  13. Rita Azevedo; Janine Soares; Andreia Peixoto; Sofia Cotton; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira. "Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology". Urologic Oncology: Seminars and Original Investigations 36 5 (2018): 221-236. https://doi.org/10.1016/j.urolonc.2018.02.004.
    10.1016/j.urolonc.2018.02.004
  14. Carrascal MA; Silva M; Ferreira JA; Azevedo R; Ferreira D; Silva AMN; Ligeiro D; et al. "A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer.". Biochimica et biophysica acta (2018): http://europepmc.org/abstract/med/29777742.
    10.1016/j.bbagen.2018.05.013
  15. Rita Azevedo; André M.N. Silva; Celso A. Reis; Lúcio Lara Santos; José Alexandre Ferreira. "In silico approaches for unveiling novel glycobiomarkers in cancer". Journal of Proteomics 171 (2018): 95-106. https://doi.org/10.1016/j.jprot.2017.08.004.
    10.1016/j.jprot.2017.08.004
  16. Luís Lima; Manuel Neves; Marta I. Oliveira; Lorena Dieguez; Rui Freitas; Rita Azevedo; Cristiana Gaiteiro; et al. "Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases". Urologic Oncology: Seminars and Original Investigations 35 12 (2017): 675.e1-675.e8. https://doi.org/10.1016/j.urolonc.2017.08.012.
    10.1016/j.urolonc.2017.08.012
  17. Azevedo, Rita. "Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?". Oncotarget (2017):
    10.18632/oncotarget.19433
  18. Cotton S; Azevedo R; Gaiteiro C; Ferreira D; Lima L; Peixoto A; Fernandes E; et al. "Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced stage bladder tumours.". (2017): http://europepmc.org/abstract/med/28156048.
    10.1002/1878-0261.12035
  19. Peixoto, A.; Fernandes, E.; Gaiteiro, C.; Lima, L.; Azevedo, R.; Soares, J.; Cotton, S.; et al. "Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension". Oncotarget 7 39 (2016): 63138-63157. http://www.scopus.com/inward/record.url?eid=2-s2.0-84994050563&partnerID=MN8TOARS.
    10.18632/oncotarget.11257
  20. Lima, A.; Bernardes, M.; Azevedo, R.; Seabra, V.; Medeiros, R.; Lima A; Bernardes M; et al. "Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome". Pharmacogenomics 17 15 (2016): 1649-1674. http://www.scopus.com/inward/record.url?eid=2-s2.0-84991251048&partnerID=MN8TOARS.
    10.2217/pgs-2016-0067
  21. Azevedo R; Ferreira JA; Peixoto A; Neves M; Sousa N; Lima A; Santos LL. "Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review.". (2015): http://europepmc.org/abstract/med/26196222.
    10.1016/j.jconrel.2015.07.002
  22. Azevedo, Rita; Bernardes, Miguel; Fonseca, João; Lima, Aurea. "Smartphone application for rheumatoid arthritis self-management: cross-sectional study revealed the usefulness, willingness to use and patients’ needs". Rheumatology International 1 (2015): 1-11. http://link.springer.com/article/10.1007%2Fs00296-015-3270-9.
    Published • 10.1007/s00296-015-3270-9
  23. Azevedo, Rita; Sousa, Hugo; Monteiro, Joaquim; Lima, Aurea. "Future perspectives of Smartphone applications for rheumatic diseases self-management". Rheumatology International 35 3 (2015): 419-431. http://link.springer.com/article/10.1007%2Fs00296-014-3117-9.
    Published • 10.1007/s00296-014-3117-9
  24. Lima A; Bernardes M; Azevedo R; Medeiros R; Seabra V. "Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?". (2015): http://europepmc.org/abstract/med/26086825.
    10.3390/ijms160613760
  25. Lima A; Sousa H; Monteiro J; Azevedo R; Medeiros R; Seabra V; Lima, Aurea; et al. "Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.". Pharmacogenomics 15 12 (2014): 1611-1635. http://europepmc.org/abstract/med/25340735.
    Published • 10.2217/pgs.14.116
  26. Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V. "SLC19A1, SLC46A1 and SLCO1B1 Polymorphisms As Predictors Of Methotrexate-Related Toxicity In Portuguese Rheumatoid Arthritis Patients.". (2014): http://europepmc.org/abstract/med/25124723.
    10.1093/toxsci/kfu162
  27. Lima, Aurea; Monteiro, Joaquim; Bernardes, Miguel; Sousa, Hugo; Azevedo, Rita; Seabra, Vítor; Medeiros, Rui. "Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: Implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms". BioMed Research International 2014 368681 (2014): 1-14.
    Published • 10.1155/2014/368681
  28. Lima, Aurea; Bernardes, Miguel; Sousa, Hugo; Azevedo, Rita; Costa, Lúcia; Ventura, Francisco; Seabra, Vítor; Medeiros, Rui. "SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients". Pharmacogenomics 15 6 (2014): 807-820.
    Published • 10.2217/pgs.13.244
  29. Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R. "Role of Key TYMS Polymorphisms on Methotrexate Therapeutic Outcome in Portuguese Rheumatoid Arthritis Patients.". (2014): http://europepmc.org/abstract/med/25279663.
    10.1371/journal.pone.0108165
  30. Lima, Aurea; Azevedo, Rita; Sousa, Hugo; Seabra, Vítor; Medeiros, Rui. "Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics". Pharmacogenomics 14 11 (2013): 1337-1413.
    Published • 10.2217/pgs.13.118

Other

Other output
  1. Glycoproteogenomics characterizes the CD44 splicing code driving bladder cancer invasion. 2021. Cristiana Gaiteiro; Janine Soares; Marta Relvas-Santos; Andreia Peixoto; Dylan Ferreira; Andreia Brandão; Elisabete Fernandes; et al. https://doi.org/10.1101/2021.09.04.458979.
    10.1101/2021.09.04.458979
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2018/06/16 CD44-glycoprofilling: Estabilishing the molecular basis for targeted therapeutics in bladder cancer 29th International Carbohydrate Symposium – ICS2018
Faculdade de Ciências da Universidade de Lisboa (Lisboa, Portugal)
2017/09/12 Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced stage bladder tumours 12ª Reunião do Grupo de Glúcidos – GLUPOR12
Universidade de Aveiro (Aveiro, Portugal)

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2014/05/22 - 2014/05/23 Guest Speaker of the theme “Geração ‘Smartphones’”. XV Scientific Conference of Pharmaceutical Sciences, Higher Institute of Health Sciences - North (ISCS-N), “Estratégias terapêuticas personalizadas”. Organization: Student association of ISCS-N. Exponor.
Meeting
 XV Scientific Conference of Pharmaceutical Sciences
Instituto Universitário de Ciências da Saúde, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2016/03/10 - 2016/03/10 Theoretical and Practical Course of Molecular Biology Applied to Oncology 1st Precision Oncology Meeting - Porto – “From basic research to clinical practice” Universidade Fernando Pessoa, Portugal
Distinctions

Award

2013 Best student 2011-2012 of Degree in Biochemistry at ISCS-N
Cooperativa de Ensino Superior Politécnico e Universitário, CESPU, Portugal